Sort   by:  
 Page size 
UnknownPrognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1.
Not available
S-EPMC8945292 | biostudies-literature
UnknownPatterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.
Not available
S-EPMC4588395 | biostudies-literature
UnknownThe lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Not available
S-EPMC4741628 | biostudies-literature
UnknownDifferent methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Not available
S-EPMC7809812 | biostudies-literature
UnknownMass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Not available
S-EPMC9198943 | biostudies-literature
UnknownReinforcement of the Standard Therapy with Two Infusions of Convalescent Plasma for Patients with COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC9181298 | biostudies-literature
UnknownA critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry
Not available
S-EPMC12915834 | biostudies-literature
UnknownZoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Not available
S-EPMC4800701 | biostudies-literature
UnknownThe expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Not available
S-EPMC4635188 | biostudies-literature
UnknownDiverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Not available
S-EPMC11724937 | biostudies-literature
Sort   by:  
 Page size